Clinical experience with Idebenone (Raxone) in the treatment of patients with Lebers Hereditary Optic Neuropathy (LHON)

An increasing body of evidence indicates that idebenone has therapeutic potential for the treatment of LHON. Data from a randomized placebo-controlled study (RHODOS) and from case reports and retrospective cohort studies demonstrate that patients with established vision loss may benefit from idebenone treatment and recover visual acuity (VA). This study reports VA outcomes for LHON patients with recent onset of vision loss who received idebenone (Raxone) treatment under an ongoing Expanded Access Program (EAP).